"10.1371_journal.pone.0013945","plos one","2010-11-29T00:00:00Z","Anne J Blood; Dan V Iosifescu; Nikos Makris; Roy H Perlis; David N Kennedy; Darin D Dougherty; Byoung Woo Kim; Myung Joo Lee; Shirley Wu; Sang Lee; Jesse Calhoun; Steven M Hodge; Maurizio Fava; Bruce R Rosen; Jordan W Smoller; Gregory P Gasic; Hans C Breiter; for the Phenotype Genotype Project on Addiction and Mood Disorders","Depression Clinic and Research Program, Mood and Motor Control Laboratory, Addiction Research Program, Laboratory of Neuroimaging and Genetics, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America; Psychiatric and Neurodevelopmental Genetics Unit and Center for Human Genetic Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America; Motivation and Emotion Neuroscience Collaboration (MENC) and Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America; Center for Morphometric Analysis and Center for Integrative Informatics, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America; Mount Sinai School of Medicine, New York, New York, United States of America","Conceived and designed the experiments: AJB DI RHP BWK MF BR JWS HCB. Performed the experiments: AJB DI RHP DDD BWK MJL SW SL JC JWS GPG HCB. Analyzed the data: AJB DI NM DNK DDD BWK MJL SW SL JC SMH MF JWS GPG HCB. Contributed reagents/materials/analysis tools: AJB NM RHP DNK BWK MJL SMH BR HCB. Wrote the paper: AJB HCB. Contributed revisions to the manuscript drafts produced by AJB and HCB: DI NM RHP DNK DDD BWK MJL SW SL JC SMH MF BR JWS GPG.","The authors have included all potential competing interests as follows. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. Dr. Iosifescu has received research support from Aspect Medical Systems, Forest Laboratories and Janssen Pharmaceutica; he has been a consultant for Forest Laboratories, Gerson Lehrman Group and Pfizer, Inc., and he has been a Speaker for Cephalon, Inc., Eli Lilly and Co., Forest Laboratories and Pfizer, Inc. Dr. Dougherty currently has research support and does consulting with honoraria for Medtronic, Eli Lilly, Brand Ideas, and McNeil, does consulting with honoraria for Reed Elsevier, and has research support from Cyberonics. In the past (more than one year ago), he has had research support and done consulting with honoraria for Northstar Neuroscience, has done consulting with honoraria for Jazz Pharmaceuticals, Wyeth, Bristol Myers Squibb, Trancept Pharmaceuticals, Cyberonics, JK Associates, Inc., American Psychiatric Publishing, Inc., Advocate Health and Hosp. Corp., DHHS/NIH, Leering Swann LLC, Oxford University Press, Professional Practice Group/Psychiatry Syracuse, and Y&R Inc. DBA Sudler & Henessy, and has had research support from Forest and Cephalon. Dr. Rosen is an MRI and PET research sponsor for Siemens. Dr. Fava has received research support from Abbott Laboratories, Alkermes, Aspect Medical Systems, Astra-Zeneca, BioResearch, BrainCells, Inc., Bristol-Myers Squibb Company, Cephalon, Clinical Trial Solutions, LLC, Eli Lilly and Company, Forest Pharmaceuticals Inc., Ganeden, GlaxoSmithKline, J and J Pharmaceuticals, Lichtwer Pharma GmbH, Lorex Pharmaceuticals, NARSAD, NCCAM, NIDA, NIMH, Novartis, Organon Inc., PamLab, LLC, Pfizer Inc, Pharmavite, Roche, Sanofi-Aventis, Shire, Solvay Pharmaceuticals, Inc., Synthelabo, Wyeth-Ayerst Laboratories. He also reported performing advising/consultation with Abbott Laboratories, Amarin, Aspect Medical Systems, Astra-Zeneca, Auspex Pharmaceuticals, Bayer AG, Best Practice Project Management, Inc, BioMarin Pharmaceuticals, Inc.,Biovail Pharmaceuticals, Inc., BrainCells, Inc, Bristol-Myers Squibb Company, Cephalon, Clinical Trials Solutions, LLC, CNS Response, Compellis, Cypress Pharmaceuticals, Dov Pharmaceuticals, Eisai, Inc., Eli Lilly and Company, EPIX Pharmaceuticals, Euthymics Bioscience, Inc., Fabre-Kramer, Pharmaceuticals, Inc., Forest Pharmaceuticals Inc., GlaxoSmithKline, Grunenthal GmBH, Janssen Pharmaceutica, Jazz Pharmaceuticals, J and J Pharmaceuticals, Knoll Pharmaceutical Company, Labopharm, Lorex Pharmaceuticals, Lundbeck, MedAvante Inc., Merck, Methylation Sciences, Neuronetics, Novartis, Nutrition 21, Organon Inc., PamLab, LLC, Pfizer Inc, PharmaStar, Pharmavite, Precision Human Biolaboratory, PsychoGenics, Psylin Neurosciences, Inc., Ridge Diagnostics, Inc., Roche, Sanofi-Aventis, Sepracor, Schering-Plough, Solvay Pharmaceuticals, Inc., Somaxon, Somerset Pharmaceuticals, Synthelabo, Takeda, Tetragenex, TransForm Pharmaceuticals, Inc., Transcept Pharmaceuticals, Vanda Pharmaceuticals Inc, Wyeth-Ayerst Laboratories. He reported performing speaking/publishing for Adamed, Co., Advanced Meeting Partners, American Psychiatric Association, American Society of Clinical Psychopharmacology, Astra-Zeneca, Belvoir, Boehringer-Ingelheim, Bristol-Myers Squibb Company, Cephalon, Eli Lilly and Company, Forest Pharmaceuticals Inc., GlaxoSmithKline, Imedex, Novartis, Organon Inc., Pfizer Inc, PharmaStar, MGH Psychiatry Academy/Primedia, MGH Psychiatry Academy/Reed-Elsevier, UBC, Wyeth-Ayerst Laboratories. He reported having equity holdings in Compellis, receiveing royalty/patent or other income from SPCD and for a combination of azapirones and bupropion in MDD, and copyright royalties for the MGH CPFQ, SFI, ATRQ, DESS, and SAFER. Drs. Blood, Makris, Perlis, Kennedy, Smoller, Gasic, and Breiter have no relevant financial interest in this manuscript. Byoung Woo Kim, Myung Joo Lee, Shirley Wu, Sang Lee, Jesse Calhoun, and Steven Hodge also have no relevant financial interest in this manuscript.","2010","11","Anne J Blood","AJB",18,TRUE,8,12,15,2,TRUE,TRUE,TRUE,1,"18",TRUE
